HSBC Mutual Fund decreased its stake in Neuland Laboratories from 1.82% to 1.55% by selling 35,189 shares. The value of the sold shares was approximately ₹64.86 crore, based on the share price of ₹18,434.00.
A pharmaceutical manufacturer engaged in the production and distribution of bulk drugs, Neuland Labs serves both domestic and international markets through its integrated operations. The company specializes in manufacturing active pharmaceutical ingredients and provides contract manufacturing services to global pharmaceutical companies. Its facilities are designed to meet stringent international quality and regulatory standards for pharmaceutical production.
Indian arm of HSBC Asset Management, the investment arm of HSBC Group with over USD 600 billion in global AUM. Manages over Rs 1 lakh crore in India across equity, debt and hybrid schemes. Previously known for integration of L&T Mutual Fund schemes after acquiring it from L&T Finance in 2022, which significantly expanded the franchise.